Przejdź do
Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.
Wybierz wielkość
Zmień widok
| Rozmiar/SKU | Dostępność | Cena netto |
|---|
Informacje o tej pozycji
Wzór empiryczny (zapis Hilla):
C32H39NO5
Numer CAS:
Masa cząsteczkowa:
517.66
UNSPSC Code:
41116107
Informacje o cenach i dostępności nie są obecnie dostępne.
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomócgrade
pharmaceutical primary standard
agency
USP
manufacturer/tradename
USP
application(s)
pharmaceutical small molecule
format
neat
storage temp.
-10 to -25°C
General description
Fexofenadine N-Oxide is a USP Pharmaceutical Analytical Impurity (PAI).
USP PAI are a product line of impurities suitable for research and analytical purposes, which help to ensure the quality and safety of medicines.
Associated Drug Substance: Fexofenadine
Therapeutic Area: Antihistamines
USP PAI are a product line of impurities suitable for research and analytical purposes, which help to ensure the quality and safety of medicines.
Associated Drug Substance: Fexofenadine
Therapeutic Area: Antihistamines
Application
Fexofenadine N-Oxide is intended for use in analytical testing to detect, identify, and measure pharmaceutical impurities.
Features and Benefits
USP PAI advance your early analytical R&D and process development. PAI can be used in the following applications:
1. Conduct analytical tests during early formulation feasibility studies.
2. Determine degradation impurities produced during stress studies.
3. Develop, validate, and transfer analytical methods.
4. Perform spiking studies during process R&D to demonstrate depletion upon recrystallization.
5. Record retention times and/or spectra
6. Determine relative response factors.
7. Identify unknown impurities that formed during ICH stability conditions.
8. Identify impurities that are present in the Reference Listed Drug
9. Test for and profile impurities not listed in drug substance and drug product monographs.
1. Conduct analytical tests during early formulation feasibility studies.
2. Determine degradation impurities produced during stress studies.
3. Develop, validate, and transfer analytical methods.
4. Perform spiking studies during process R&D to demonstrate depletion upon recrystallization.
5. Record retention times and/or spectra
6. Determine relative response factors.
7. Identify unknown impurities that formed during ICH stability conditions.
8. Identify impurities that are present in the Reference Listed Drug
9. Test for and profile impurities not listed in drug substance and drug product monographs.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Ta strona może zawierać tekst przetłumaczony maszynowo.
1 of 1
Ta pozycja | |||
|---|---|---|---|
| description United States Pharmacopeia (USP) Reference Standard | description United States Pharmacopeia (USP) Reference Standard | description United States Pharmacopeia (USP) Reference Standard | description - |
| application(s) pharmaceutical small molecule | application(s) pharmaceutical | application(s) pharmaceutical (small molecule) | application(s) - |
| format neat | format neat | format neat | format neat |
| grade pharmaceutical primary standard | grade pharmaceutical primary standard | grade pharmaceutical primary standard | grade pharmaceutical primary standard |
| storage temp. -10 to -25°C | storage temp. - | storage temp. - | storage temp. 2-30°C |
| manufacturer/tradename USP | manufacturer/tradename USP | manufacturer/tradename USP | manufacturer/tradename USP |
| agency USP | agency USP | agency USP | agency USP |
Klasa składowania
11 - Combustible Solids
Co się dzieje?
WGK 3
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Wybierz jedną z najnowszych wersji:
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
